SCHEMBL7422804

SCHEMBL7422804

CCOP(=O)(C=C1CCN(C(=O)OC(C)(C)C)CC1)OCC

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 2/20 0.43
ADORA1 P30542 2/20 0.41
USP2 O75604 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
ESR2 Q92731 1/20 0.40
KDM4E B2RXH2 2/20 0.37
MAPT P10636 1/20 0.37
THRB P10828 1/20 0.37
NR1H2 P55055 1/20 0.37
PKM P14618 1/20 0.37
DDB1 Q16531 1/20 0.37
CRBN Q96SW2 1/20 0.37
HPGD P15428 1/20 0.36
HTT P42858 1/20 0.36
ATM Q13315 1/20 0.36
GRM1 Q13255 1/20 0.35
GPR119 Q8TDV5 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24510152 0.95 GRM5 (0.40) GRM5ADORA1USP2SMN1; SMN2ESR2
SCHEMBL29052674 0.95 GRM5 (0.40) GRM5ADORA1USP2SMN1; SMN2ESR2
SCHEMBL30105939 0.78 NAMPT (0.37) HPGDMEN1KMT2A
SCHEMBL803581 0.78 ADORA1 (0.48) GRM5ADORA1USP2SMN1; SMN2ESR2
SCHEMBL10253506 0.78 USP2 (0.51) GRM5ADORA1USP2SMN1; SMN2ESR2
SCHEMBL17282284 0.77 USP2 (0.47) GRM5ADORA1USP2SMN1; SMN2ESR2
SCHEMBL29052698 0.77 GRM5 (0.31) GRM5
SCHEMBL2948300 0.75 USP2 (0.49) GRM5ADORA1USP2SMN1; SMN2ESR2
SCHEMBL843458 0.75 USP2 (0.49) GRM5ADORA1USP2SMN1; SMN2ESR2
SCHEMBL14419067 0.75 USP2 (0.49) GRM5ADORA1USP2SMN1; SMN2ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11111259-B2 Acylsulfonamide derivatives for treating senescence-associated diseases and disorders UNITY BIOTECHNOLOGY, INC. (US) 2021-09-07 US disclosed
US-20200291050-A1 ACYLSULFONAMIDE DERIVATIVES FOR TREATING SENESCENCE-ASSOCIATED DISEASES AND DISORDERS UNITY BIOTECHNOLOGY, INC. 2020-09-17 US disclosed
EP-0815103-A1 TRYPSIN AND THROMBIN INHIBITORS Novartis AG (CH) 1998-01-07 EP disclosed
WO-1996029327-A1 TRYPSIN AND THROMBIN INHIBITORS NOVARTIS AG (CH) 1996-09-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11111259-B2 Acylsulfonamide derivatives for treating senescence-associated diseases and disorders ACAT1, ARSA, GLA GRM5 4578/4885ADORA1 4035/4885USP2 1093/4885
US-20200291050-A1 ACYLSULFONAMIDE DERIVATIVES FOR TREATING SENESCENCE-ASSOCIATED DISEASES AND DISORDERS ACAT1, ARSA, GLA GRM5 4578/4885ADORA1 4035/4885USP2 1093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.